Feb. 3 at 5:41 PM
$CVM
Lil joh … this comment reads like someone who learned biotech from Madlibs🤣
The FDA didn’t block CVM because it was “too effective” or “too safe.” That’s not how approvals work — and pretending otherwise just tells everyone you don’t understand clinical development.
Here’s what actually happened (feel free to take notes):
• Safety alone does not get drugs approved.
You still need clean, pre-specified efficacy endpoints. CVM didn’t deliver them.
• CVM botched its trial design and then tried to argue after the fact.
Moving goalposts, post-hoc endpoint gymnastics, and “signal chasing” after unblinding is the fastest way to get laughed out of an FDA review.
• They treated the FDA like opposing counsel instead of a regulator.
Hiring lawyers to debate science instead of fixing protocol flaws is amateur hour. FDA isn’t court — you don’t win by arguing intent.
• Execution was sloppy for a company screaming “life-saving.”
Endless delays, inconsistent sites, questionable data integrity. If this drug were the miracle you think it is, the trial wouldn’t look like a group project done the night before it was due.
• Management chose denial over accountability.
Rather than admit mistakes, they blamed the FDA, politics, timing, moon phases — everything except their own incompetence.
• Shareholders paid for it.
Dilution, missed timelines, recycled narratives. Management kept cashing checks while retail kept buying the fairy tale.
This wasn’t the FDA “blocking” anything.
This was CVM failing basic biotech execution and then crying foul.
If you want to be mad, be mad at:
– bad trial design
– bad regulatory strategy
– bad leadership
But blaming the FDA just tells everyone you don’t understand how drugs actually get approved.
Snowflake be snowflaking
Waaah. Waaaah
What a crybaby lil pew say
Take some accountability
Or do you believe what little birdie was saying all the time? I got you!🤡
Daddy won
Sushi won
Adam won
Woof woof
Cheers
